[Therapy for male patients with sexual dysfunction].

Area of Science:

• Urology
• Pharmacology

Context:

• Erectile dysfunction (ED) and premature ejaculation (PE) are common sexual health concerns.
• First-line treatments for ED include phosphodiesterase type 5 inhibitors.

Purpose:

• To review current therapeutic options for erectile dysfunction and premature ejaculation.
• To inform healthcare providers about the efficacy and safety of various treatment modalities.

Summary:

• Phosphodiasterase type 5 inhibitors (sildenafil, vardenafil, tadalafil) are safe first-line ED treatments, suitable for patients with stable cardiovascular disease.
• Alternative ED therapies include intraurethral/intracavernous alprostadil, vacuum devices, and penile prostheses.
• PE management involves behavioral therapies (stop-start, squeeze) and pharmacotherapy, including topical lidocaine/prilocaine and oral SSRIs (paroxetine, fluoxetine, sertraline).
• Dapoxetine, a selective serotonin reuptake inhibitor, is an approved oral treatment for PE with a short half-life.

Impact:

• Provides a comprehensive overview of ED and PE treatments, aiding clinical decision-making.
• Highlights the safety profile of PDE5 inhibitors in patients with cardiovascular conditions.
• Discusses emerging treatments like dapoxetine for premature ejaculation, improving patient outcomes.